Kinnate Biopharma (KNTE): Price and Financial Metrics

Kinnate Biopharma (KNTE): $4.24

-0.06 (-1.40%)

POWR Rating

Component Grades








Add KNTE to Watchlist
Sign Up

Industry: Biotech




#274 of 380

in industry

KNTE Price/Volume Stats

Current price $4.24 52-week high $15.86
Prev. close $4.30 52-week low $2.32
Day low $4.14 Volume 338,900
Day high $4.40 Avg. volume 303,679
50-day MA $4.31 Dividend yield N/A
200-day MA $7.46 Market Cap 197.47M

KNTE Stock Price Chart Interactive Chart >

Kinnate Biopharma (KNTE) Company Bio

Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA.

KNTE Latest News Stream

Event/Time News Detail
Loading, please wait...

KNTE Latest Social Stream

Loading social stream, please wait...

View Full KNTE Social Stream

Latest KNTE News From Around the Web

Below are the latest news stories about KINNATE BIOPHARMA INC that investors may wish to consider to help them evaluate KNTE as an investment opportunity.

11 Stocks with Heavy Insider Buying in 2023

In this article, we will take a look at the 11 stocks with heavy insider buying in 2023. To see more such companies, go directly to 5 Stocks with Heavy Insider Buying in 2023. Insider trading activity has always invited interest and controversy from investors and authorities. Recent history has proven time and again that […]

Yahoo | May 22, 2023

Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates

Presented positive monotherapy dose escalation data for exarafenib, an investigational pan-RAF inhibitor, at the 2023 AACR Annual Meeting Provided update on ongoing exarafenib monotherapy dose expansion; data-informed strategy prioritizes enrollment in BRAF Class II-driven solid tumors Disclosed early, compelling responses with exarafenib plus binimetinib from the ongoing dose escalation combination arm, primarily in NRAS mutant melanoma Announced the addition of two new development candidates t

Yahoo | May 11, 2023

Why Earnings Season Could Be Great for Kinnate Biopharma (KNTE)

Kinnate Biopharma (KNTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | May 10, 2023

7 Stocks With Promising Upside Potential for 100% Returns

If you still want to gamble even during this market environment, these are the stocks with 100% upside potential.

Josh Enomoto on InvestorPlace | May 7, 2023

Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance

KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023KIN-8741, a highly selective c-MET inhibitor designed to cover acquired resistance in non-small cell lung cancer and other advanced adult solid tumors, is expected to enter the clinic in the first half of 2024Kinnate to evaluate strategic alternatives for its CDK12 program ~$231 million of cash, cash equivalents and investments as of Mar

Yahoo | April 17, 2023

Read More 'KNTE' Stories Here

KNTE Price Returns

1-mo 61.22%
3-mo -15.20%
6-mo -39.86%
1-year -44.50%
3-year N/A
5-year N/A
YTD -30.49%
2022 -65.58%
2021 -55.46%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!